Fabrizio Facchinetti Selected Research

Type 4 Cyclic Nucleotide Phosphodiesterases

10/2022	The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation.
4/2022	The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils.
1/2021	The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs.
1/2021	Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease.
1/2019	The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.
12/2017	Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
3/2015	CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabrizio Facchinetti Research Topics

Disease

21	Chronic Obstructive Pulmonary Disease (COPD) 10/2022 - 11/2007
11	Asthma (Bronchial Asthma) 01/2022 - 02/2014
8	Inflammation (Inflammations) 04/2022 - 05/2009
6	Pneumonia (Pneumonitis) 01/2022 - 11/2007
4	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2022 - 02/2014
3	Lung Diseases (Lung Disease) 04/2022 - 03/2015
3	Hypothermia 04/2022 - 01/2018
3	Brain Diseases (Brain Disorder) 04/2022 - 01/2019
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 01/2019
3	Nausea 01/2021 - 03/2015
3	Hypoxia (Hypoxemia) 10/2019 - 01/2018
3	Ischemia 10/2019 - 01/2018
3	Alzheimer Disease (Alzheimer's Disease) 12/2007 - 09/2005
2	Diarrhea 01/2021 - 01/2020
2	Pulmonary Hypertension 12/2019 - 05/2019
2	Amyloid Plaque 02/2006 - 09/2005
1	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 04/2022
1	Diseases Newborn Infant 01/2022
1	Cystic Fibrosis (Mucoviscidosis) 01/2022
1	Chronic Bronchitis 01/2021
1	COVID-19 01/2021
1	Abdominal Pain (Pain, Abdominal) 01/2021
1	Atopic Dermatitis (Atopic Eczema) 01/2021
1	Weight Loss (Weight Reduction) 01/2021
1	Fibrosis (Cirrhosis) 01/2020
1	Headache (Headaches) 01/2020
1	Human Influenza (Influenza) 01/2020
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Psoriatic Arthritis 01/2020
1	Pulmonary Arterial Hypertension 12/2019
1	Neuroinflammatory Diseases 10/2019
1	Brain Injuries (Brain Injury) 10/2019
1	Hypertension (High Blood Pressure) 05/2019
1	Reperfusion Injury 01/2019
1	Airway Remodeling 09/2017
1	Infections 01/2016
1	Acute Monocytic Leukemia (Acute Monoblastic Leukemia) 03/2015
1	Eosinophilia 03/2015

Drug/Important Bio-Agent (IBA)

12	Phosphodiesterase 4 InhibitorsIBA 04/2022 - 02/2014
11	tanimilastIBA 10/2022 - 03/2015
7	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 10/2022 - 03/2015
5	Pharmaceutical PreparationsIBA 04/2022 - 09/2005
5	SmokeIBA 11/2012 - 11/2007
3	GlucocorticoidsIBA 10/2022 - 01/2013
3	RoflumilastIBA 01/2021 - 01/2016
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019 - 01/2013
3	Interleukin-8 (Interleukin 8)IBA 11/2012 - 11/2007
3	AldehydesIBA 07/2012 - 11/2007
2	EnzymesIBA 01/2021 - 12/2017
2	Protein Kinases (Protein Kinase)IBA 12/2019 - 05/2019
2	rho-Associated KinasesIBA 12/2019 - 05/2019
2	MonocrotalineIBA 12/2019 - 05/2019
2	Oxygen (Dioxygen)IBA 10/2019 - 01/2018
2	beclomethasone 17-monopropionateIBA 01/2019 - 01/2013
2	MelatoninIBA 01/2019 - 01/2018
2	CytokinesIBA 01/2019 - 01/2013
2	AntigensIBA 03/2015 - 06/2007
2	Acrolein (Aqualin)IBA 07/2012 - 01/2012
2	Amyloid beta-PeptidesIBA 12/2007 - 02/2006
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 04/2007 - 09/2005
1	Bronchodilator Agents (Bronchodilators)IBA 10/2022
1	Adenosine (Adenocard)FDA LinkGeneric 01/2022
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2022
1	Peptides (Polypeptides)IBA 01/2022
1	EndotoxinsIBA 01/2022
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2022
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2022
1	Ion Channels (Ion Channel)IBA 01/2022
1	Immunomodulating AgentsIBA 01/2021
1	apremilastIBA 01/2020
1	Bromodeoxyuridine (BrdU)IBA 01/2020
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Y 27632IBA 12/2019
1	Endothelin Receptor AntagonistsIBA 12/2019
1	Vasoconstrictor AgentsIBA 12/2019
1	macitentanIBA 12/2019
1	ChemokinesIBA 11/2019
1	Biomarkers (Surrogate Marker)IBA 10/2019
1	Therapeutic UsesIBA 05/2019
1	Interleukin-17 (Interleukin 17)IBA 01/2019
1	Interleukin-13IBA 01/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019
1	Interleukin-2 (IL2)IBA 01/2019
1	compound 17IBA 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	Budesonide (Pulmicort)FDA LinkGeneric 01/2018
1	Tiotropium Bromide (Spiriva)FDA Link 09/2017
1	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 09/2017
1	Methacholine Chloride (Methacholine)FDA Link 09/2017
1	Cholinergic Antagonists (Anticholinergics)IBA 09/2017
1	SteroidsIBA 01/2016
1	6- ((3- ((dimethylamino)carbonyl)phenyl)sulfonyl)- 8- methyl- 4- ((3- methyloxyphenyl)amino)- 3- quinolinecarboxamideIBA 03/2015
1	Ketamine FDA LinkGeneric 03/2015
1	OvalbuminIBA 03/2015
1	OxidesIBA 03/2015

Therapy/Procedure

7	Therapeutics 04/2022 - 01/2016
2	Induced Hypothermia 04/2022 - 01/2019